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Inﬂ  uenza A 
Pandemic (H1N1) 
2009 Virus and HIV
To the Editor: The effects of in-
ﬂ  uenza A pandemic (H1N1) 2009 vi-
rus infection in HIV-infected patients 
are unknown. We describe an HIV-
infected patient with severe pandemic 
(H1N1) 2009 virus infection.
The patient was a 37-year-old, 
HIV-positive, former intravenous drug 
user in a methadone-substitution pro-
gram. She had a history of smoking, 
hepatitis C, and mild chronic obstruc-
tive pulmonary disease not requir-
ing treatment. Since 2007 her viral 
load had been <50 HIV RNA copies/
mL, for which she received tenofovir, 
emtricitabine, and lopinavir/ritonavir. 
Her CD4 count in March 2009 was 
542 cells/μL (25%).
On June 24, 2009, the patient 
entered the Hospital Universitario La 
Paz after 3 days of dyspnea and fever, 
without cough or sputum. Temperature 
was 39°C, blood pressure 118/74 mm 
Hg, pulse rate 110 beats per minute, 
respiratory rate 30 breaths per minute, 
and oxygen saturation 85% on room 
air (fraction of inspired oxygen [FiO2] 
21%).  Lung wheezes were audible. 
Laboratory testing showed leukocyto-
sis with neutrophilia and oxygen par-
tial pressure (pO2) 70.9 mm Hg (FiO2 
21%). Chest radiograph ﬁ  ndings were 
consistent with bacterial pneumonia 
(Figure, panel A). Empirical treatment 
with clarithromycin and ceftriaxone 
was started. After full clinical recov-
ery, the patient was discharged on June 
30 and prescribed oral clarithromycin 
and ceﬁ  xime.
At a routine follow-up visit on 
July 2, the woman was asymptomatic 
and had fewer leukocytes and neutro-
phils, creatine kinase 800 U/L (refer-
ence <145), and lactate dehydrogenase 
373 U/L (reference <247). On July 3, 
she returned to the hospital because 
of dyspnea and high fever (38.5°C). 
Oxygen saturation was 75%, pO2 33.8 
mm Hg (FiO2 21%), and blood pres-
sure 90/54 mm Hg. Chest radiographs 
showed alveolar inﬁ  ltrates in the right 
lower lobe (Figure, panel B). Because 
her deterioration was attributed to 
nosocomial infection, she was given 
meropenem, linezolid, and levoﬂ  oxa-
cine and was hospitalized. Within the 
next 96 hours, her condition deteriorat-
ed further to drowsiness, hypotension, 
oxygen saturation 92%, pO2 60.5 mm 
Hg (FiO2 50%), and new radiographic 
bilateral alveolo-interstitial inﬁ  ltrates 
appeared (Figure, panel C).
On July 7, real-time reverse tran-
scription–PCR of a nasopharyngeal 
swab conﬁ  rmed inﬂ  uenza A pandemic 
(H1N1) 2009 virus (1). Other infec-
tious causes for bacterial and viral 
pneumonia were excluded. The pa-
tient received mechanical ventilation 
for 7 days and oseltamivir. She was 
discharged after 21 days. She still had 
dyspnea after exertion and radiologic 
sequelae on chest radiograph (Figure, 
panel D).
No patients or healthcare workers 
who had had contact with the patient 
had conﬁ  rmed pandemic (H1N1) 2009 
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Figure. Chest radiographs of 37-year-old, HIV-positive woman with severe pandemic 
(H1N1) 2009 virus infection, 2009. A) June 24, alveolar inﬁ  ltrate in the right lower lobe. 
B) July 3, minimal pleural effusion, alveolar inﬁ  ltrate on right lower lobe, and possibly left 
lower lobe inﬁ  ltrate. C) July 6, bilateral alveolo-intertitial inﬁ  ltrates. D) July 29, bilateral 
peribroncovascular thickening with ﬁ  bro-cicatricial changes; conserved lung volumes.LETTERS
virus infection. The patient shared a 
room with a highly immunocompro-
mised HIV patient, who was negative 
for pandemic (H1N1) 2009 virus but 
received oseltamivir as prophylaxis.
Few data are available on pan-
demic (H1N1) 2009 virus infection in 
immunocompromised patients. Of 30 
patients with pandemic (H1N1) 2009 
in California (2), 6 had underlying con-
ditions involving immunosuppression 
but none was infected with HIV. The 
clinical course of pandemic (H1N1) 
2009 virus infection in immunocom-
promised patients was similar to that 
in nonimmunocompromised patients, 
although not all received oseltamivir. 
The patient reported here was not se-
verely inmunosuppresed; her CD4 
count was stable at >300 cells/μL.
Severe pandemic (H1N1) 2009 vi-
rus infection most commonly produc-
es fever, dyspnea, respiratory distress, 
and bilateral patchy pneumonia (3), 
which can initially be interpreted as 
bacterial pneumonia and consequently 
treated with antimicrobial drugs (2–7). 
We believe that the patient reported 
here ﬁ  rst had a community-acquired 
pneumonia with a rapid response to 
treatment and that she secondarily had 
respiratory distress caused by pandem-
ic (H1N1) 2009 virus pneumonia. We 
cannot conﬁ  rm whether the pandem-
ic (H1N1) 2009 virus infection was 
nosocomial or community acquired.
The increased creatine kinase and 
lactate dehydrogenase and lymphope-
nia in this patient resemble that report-
ed in Mexico by Perez-Padilla et al. 
(3). Although these laboratory param-
eters are unspeciﬁ  c, they could serve 
as an alert to pneumonia caused by 
pandemic (H1N1) 2009 virus instead 
of bacteria. The Centers for Disease 
Control and Prevention (CDC) recom-
mends testing all HIV-infected patients 
suspected of having pandemic (H1N1) 
2009 virus infection (8). The Spanish 
Ministry of Health and Madrid De-
partment of Health recommends this 
testing for patients with an erratic out-
come from common pneumonia.
For HIV-infected patients who 
meet case deﬁ   nitions for conﬁ  rmed, 
probable, or suspected pandemic 
(H1N1) 2009 virus infection, CDC 
recommends empiric antiviral drug 
treatment (8). There are no known 
contraindications for co-administra-
tion of oseltamivir, a neuraminidase 
inhibitor, with antiretroviral medica-
tions; no interactions have been dem-
onstrated (8,9).
Although clinical signs and treat-
ment of pandemic (H1N1) 2009 are 
similar for patients with and without 
HIV infection, HIV-infected patients 
with suspected pandemic (H1N1) 
2009 virus symptoms should be treated 
as soon as possible. CDC recommends 
the use of inﬂ  uenza antiviral drugs, but 
this recommendation might change as 
additional data on this therapy for HIV-
infected patients become available. At 
this time, however, we strongly recom-
mend use of antiviral drugs for HIV-
infected patients with suspected pan-
demic (H1N1) 2009 virus.
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Letters commenting on recent articles 
as well as letters reporting cases, 
outbreaks, or original research are 
welcome. Letters commenting on ar-
ticles should contain no more than 
300 words and 5 references; they are 
more likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
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contain no more than 800 words and 
10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
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lished and include a word count.